- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01439997
Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study
The objective of this study is to find out what the pharmacodynamic (PD) characteristics of desmopressin melt are in nocturia patients (compared to healthy volunteers and children). The main questions the investigators want to answer are:
- Are differences related to the pathophysiological factors involved in nocturia?
- Are there age/gender/size differences?
- Can the investigators identify patients who are likely to develop hyponatraemia?
- Can the investigators individualize treatment and reduce risk for hyponatraemia?
The patient will be given a prescription to buy Minirin Melt 60µg at the local pharmacy. During 30 days, the patient has to take Minirin Melt 60µg in the evening before going to bed.
There are two groups of patients:
Group A:
Patients that still have to undergo an evaluation phase, according to standard procedures (e.g. osmolality test, blood sample). This procedure is not a part of this study. The study starts when the 1st Minirin Melt tablet has been taken (= day 1).
Group B:
This group already went through the evaluation phase (by participation to study 1 or study 3 as mentioned above) and they have been prescribed Minirin Melt 60 µg ambulatory.
The study starts when the patients takes his first prescribed Minirin Melt tablet:
- On day 3 and day 7 a blood sample will be taken at the UZ Ghent for safety control (Na+, K+, creatinin, osmolality = good clinical practice guideline). These first 2 visits (day 3 and day 7) are standard procedure. If the patient is at high risk for side effects, blood has to be taken during the first 7 days.
- On day 3 the patient has to give a urine sample.
- Patients have to fill out a frequency/volume chart during the first 14 days.
- On day 30, a 3rd blood sample will be taken
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Ghent, Belgium, 9000
- University Hospital Ghent
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- written informed consent prior to the performance of any study-related activity
- patients, men and women, 18 years and older, with an average of ≥ 2 nocturnal voids per night
- evidence for nocturnal polyuria (nocturnal urine volume >33% of total volume over 24h), determined on frequency/volume chart
- Diuresis <2.5L
Exclusion Criteria:
- hypersensitivity/anaphylactic reaction on desmopressin or one of the other substances
- pregnancy
- genitourinary tract pathology (infection, tumor,...)
- urolithiasis
- suspicion or evidence of cardiac failure
- moderate to severe renal insufficiency (creatinin clearance < 60 ml/min)
- psychogenic or habitual polydipsia
- hyponatraemia or predisposition for hyponatraemia
- diabetes insipidus
- syndrome of inadequate ADH production
- suspicion or evidence of liver failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Desmopressin Melt Therapy in Nocturnal Polyuria Patients
|
Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 3.
Time Frame: At day 3 after first desmopressin intake.
|
At day 3 after first desmopressin intake.
|
|
Urine sample for urine concentration of Na+, K+, creatinin and osmolality
Time Frame: At day 3
|
At day 3
|
|
Area Under Curve (AUC) frequency/volume chart during the first 14 days
Time Frame: Every day during the first 14 days.
|
Every day during the first 14 days.
|
|
The decrease of number of nocturnal micturition episodes.
Time Frame: At day 0
|
Questionnaires at day 0 to evaluate the decrease of number of nocturnal micturition episodes.
|
At day 0
|
The decrease of the number of nocturnal micturition episodes.
Time Frame: At day 30
|
Questionnaires at day 30 to evaluate the number of nocturnal micturition episodes
|
At day 30
|
Registration of number of side effects at day 3.
Time Frame: At day 3
|
At day 3
|
|
Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 7.
Time Frame: At day 7 after first desmopressin intake
|
At day 7 after first desmopressin intake
|
|
Blood samples for plasma concentration of Na+, K+, creatinin, osmolality (safety profile)at day 30.
Time Frame: At day 30 after first desmopressin intake
|
At day 30 after first desmopressin intake
|
|
Registration of number of side effects at day 7
Time Frame: At day 7
|
At day 7
|
|
Registration of number of side effects at day 30.
Time Frame: At day 30
|
At day 30
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011/567
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nocturia
-
Winthrop University HospitalCompleted
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedNocturia Due to Nocturnal PolyuriaJapan
-
Ferring PharmaceuticalsCompletedNocturia Associated With Nocturnal PolyuriaGermany
-
Wellesley Pharmaceuticals, LLCCompleted
-
Ferring PharmaceuticalsCompletedNocturiaUnited States
-
Corporacion Parc TauliCompleted
-
Ferring PharmaceuticalsCompleted
-
Cognitive Research CorporationNovartis PharmaceuticalsWithdrawn
Clinical Trials on Desmopressin
-
University Hospital, GhentCompletedEnuresis | PolyuriaBelgium
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompletedCentral Diabetes InsipidusJapan
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompleted
-
Ferring PharmaceuticalsCompleted
-
Al-Azhar UniversityNot yet recruitingNocturnal Enuresis
-
University of Kansas Medical CenterWithdrawnKidney DamageUnited States
-
Laboratorio Elea Phoenix S.A.Completed
-
Groupe Maladies hémorragiques de BretagneRecruitingDesmopressin | Hemophilia A, Mild | Factor VIIIFrance